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Abstract
Fibroblast activation including proliferation, survival, and ECM
production is central to initiation and maintenance of fibrotic
lesions in idiopathic pulmonary fibrosis (IPF). However, druggable
molecules that target fibroblast activation remain limited. In this
study, we show that multiple pro-fibrotic growth factors, including
TGFa, CTGF, and IGF1, increase aurora kinase B (AURKB) expression
and activity in fibroblasts. Mechanistically, we demonstrate that
Wilms tumor 1 (WT1) is a key transcription factor that mediates
TGFa-driven AURKB upregulation in fibroblasts. Importantly, we
found that inhibition of AURKB expression or activity is sufficient
to attenuate fibroblast activation. We show that fibrosis induced
by TGFa is highly dependent on AURKB expression and treating
TGFa mice with barasertib, an AURKB inhibitor, reverses fibroblast
activation, and pulmonary fibrosis. Barasertib similarly attenuated
fibrosis in the bleomycin model of pulmonary fibrosis. Together,
our preclinical studies provide important proof-of-concept that
demonstrate barasertib as a possible intervention therapy for IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive
fibrotic lung disease characterized by increased proliferation and
survival of mesenchymal cells that are involved in excessive
production and deposition of extracellular matrix (ECM) proteins in
the distal areas of the lung (Wynn & Ramalingam, 2012; Barratt
et al, 2018). The median survival rate of IPF patients is 3–5 years
from diagnosis, and IPF claims more lives annually than many types
of cancer (Gribbin et al, 2006; Ley et al, 2011). The increasing
burden of IPF is not simply reflective of an aging population, as age-
adjusted mortality for IPF is increasing as well (Pardo & Selman,
2016). Currently, two FDA-approved drugs, Ofev (nintedanib) and
Esbriet (pirfenidone), are available for the treatment of patients with
IPF. However, neither of these drugs provide a cure, and both of
them are associated with several serious drug-related side effects
(King et al, 2014; Richeldi et al, 2014; Hughes et al, 2016).
Pirfenidone and nintedanib both cause gastrointestinal events, while
pirfenidone also causes skin disorders including rash and photosen-
sitivity (Costabel et al, 2014; Wollin et al, 2015; Lancaster et al,
2017; Kasam et al, 2019). Intolerance to these medicines and their
variable efficacy justify the need to identify other therapeutic alter-
natives.
In the pathogenesis of IPF, lung-resident fibroblasts have been
shown to proliferate and differentiate into contractile mesenchymal
cells, called myofibroblasts, which participate in continuous ECM
production, secretion, and deposition in distal areas of the lung
(Phan, 2008; Sontake et al, 2017). Multiple cytokines and growth
factors released by immune cells, fibrocytes, and the lung epithe-
lium are known to enhance the fibrogenic activity of lung-resident
fibroblasts (Baughman et al, 1999; Allen & Spiteri, 2002). Published
reports indicate that pathological processes in IPF are often stimu-
lated by 1) receptor tyrosine kinases activated by ligands of the
epidermal growth factor receptor (EGFR), as well as platelet-derived
growth factor (PDGF), connective tissue growth factor (CTGF),
insulin-like growth factor 1 (IGF1), basic fibroblast growth factor
(FGF), and vascular endothelial growth factor (VEGF) receptors; 2)
SMAD and non-SMAD (PI3K and MAPK) signaling pathways acti-
vated by TGFb and PDGF receptors; and 3) STAT3 and STAT6
signaling pathways activated by IL-6 cytokines (IL-6 and IL-10) and
Th2 cytokines (IL-4 and IL-13), respectively (Wilson & Wynn, 2009;
Wynn, 2011; Madala et al, 2012; Prele et al, 2012; Grimminger et al,
2015; Walton et al, 2017). These data illustrate several unanswered
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questions, but also suggest a possible redundant function and syner-
gism between multiple cytokines and fibrogenic pathways. In
support of this, inhibition of a single pathway or growth factor in
mouse models or human clinical trials has not been effective in
reversing established and ongoing fibrosis in the lung (Chaudhary
et al, 2007; Vallath et al, 2014; Raghu, 2017). As fibrosis is likely
heterogeneous in etiology and molecular pathophysiology, attempts
to block or counteract single upstream or downstream pathways
may not be sufficient to inhibit cellular processes associated with
ongoing fibrosis. Therefore, identification of converging or overlap-
ping pathways downstream of growth factors involved in fibroblast
activation could result in more effective therapies. In a recent study,
we used an unbiased chemical genomics approach to identify drug
targets that regulate multiple pro-fibrotic processes including
fibroproliferation, migration, invasiveness, and ECM production
(Sontake et al, 2017). This novel in silico screening platform has
identified several small molecule inhibitors including inhibitors of
Hsp90, tyrosine kinases, and mitotic kinases, whose gene expres-
sion profiles were inversely correlated with differentially expressed
gene networks in IPF lungs.
Aurora kinase B (AURKB) is a ubiquitously expressed mitotic
kinase that belongs to the family of serine/threonine kinase (STKs)
(Nigg, 2001; Fu et al, 2007). AURKB regulates multiple key events
during cell division, which includes, but is not limited to chromatin
condensation, chromosome bi-orientation, and cytokinesis (Kol-
lareddy et al, 2008; Lampson & Cheeseman, 2011). Moreover,
recent studies have identified interphase functions of AURKB during
various pathophysiological settings (Wu et al, 2011; Gully et al,
2012; Frangini et al, 2013). It is well-documented that overexpres-
sion of AURKB in numerous cancer types causes uncontrollable
tumor cell proliferation and helps in evading apoptotic death (Sor-
rentino et al, 2005; Jha et al, 2013; Tang et al, 2017). The role of
AURKB in fibroblast activation in the pathogenesis of IPF has
remained unexplored. We had previously shown that WT1 is a criti-
cal transcription factor that promotes fibrogenesis (Sontake et al,
2015, 2018). We recently performed RNA-seq in fibroblasts for
which WT1 was knockdown, and AURKB was identified as a major
target of WT1 (Sontake et al, 2018). Here, we show for the first time
that AURKB is upregulated in fibroblasts of IPF and a mouse models
of pulmonary fibrosis. Multiple growth factors such as TGFa, CTGF,
and IGF1 upregulate AURKB in lung fibroblasts. WT1 acts as a key
transcription factor involved in TGFa-induced AURKB expression in
fibroblasts. In support of its pro-fibrotic functions, we found that
inhibition of AURKB expression or activity attenuated proliferation,
survival, and ECM production in lung fibroblasts. In vivo studies
using the TGFa- and bleomycin-induced mouse models of
pulmonary fibrosis demonstrate that barasertib, a known AURKB
inhibitor, attenuates fibroproliferation, myofibroblast survival, and
ECM deposition in established and ongoing pulmonary fibrosis.
Results
AURKB is upregulated in IPF fibroblasts
To determine the fibroproliferative effects of multiple pro-fibrotic
growth factors on AURKB expression, we treated primary fibrob-
lasts isolated from human lungs with multiple growth factors
including TGFa, TGFb, CTGF, and IGF1. We found a significant
increase in the expression of AURKB in fibroblasts treated with
TGFa, CTGF, and IGF1 but none with TGFb (Fig 1A). To deter-
mine whether AURKB is overexpressed in IPF fibroblasts, we
isolated fibroblasts from the lungs of patients with IPF and non-
fibrotic controls and measured the amount of AURKB transcripts.
We observed a significant increase in AURKB transcripts in fibrob-
lasts of IPF compared to non-IPF controls (Fig 1B). To determine
the expression of AURKB in the lungs of IPF, we immunostained
lung sections with antibody against AURKB and observed a
marked increase in AURKB staining in spindle-shaped fibroblasts
located in subpleural regions and fibrotic foci of IPF lung tissue
compared to normal lungs (Fig 1C).
AURKB is upregulated during TGFa- and bleomycin-induced
pulmonary fibrosis
To determine whether AURKB is upregulated during TGFa-
induced pulmonary fibrosis, Western blot analysis was performed
on total lung lysates from control (CCSP/-) and TGFa (CCSP/
TGFa) mice on Dox for 6 weeks using antibodies against AURKA
and AURKB. We observed a significant increase in the protein
levels of AURKB but not AURKA in TGFa mice compared to
controls (Fig 1D). In support, we observed increased staining for
AURKB in the nucleus of spindle-shaped cells localized in the
subpleural fibrotic lesions of TGFa mice on Dox for 6 weeks, but
limited or no staining in the lungs of control mice (Fig 1E).
Further, we found that the majority of AURKB is localized in the
nucleus of vimentin-positive fibroblasts (Fig EV1). Similarly, we
observed a significant increase in AURKB protein levels in the
lungs of bleomycin-treated mice compared to saline-treated
control mice (Fig 1F).
Wilm’s tumor 1 regulates the AURKB expression
Recent studies from our laboratory have shown that WT1 is upregu-
lated in mesenchymal cells of subpleural fibrotic lung lesions and
that it contributes to pulmonary fibrosis pathogenesis (Sontake
et al, 2015). To test whether WT1 affects AURKB expression, we
knocked down WT1 expression using WT1-specific siRNA in fibrob-
lasts isolated from IPF lungs or TGFa mice on Dox for 4 weeks.
Compared to control siRNA, knockdown of WT1 was sufficient to
attenuate the expression of AURKB in lung fibroblasts isolated from
both IPF and a mouse model of TGFa-induced pulmonary fibrosis
(Fig 2A and B). We next assessed the effect of adenovirus-mediated
overexpression of WT1 on AURKB levels in fibroblasts. Overex-
pressing WT1 in fibroblasts led to a significant increase in both tran-
scripts and protein of AURKB (Figs EV2A and 2C). Knockdown of
WT1 in fibroblasts also abolished the ability of TGFa to increase
AURKB expression (Fig 2D). To determine whether WT1 is a tran-
scription factor that directly binds to AURKB, we performed a
computational analysis of the promoter region of human and mouse
AURKB and found the presence of conserved WT1 binding sites
(Fig EV2B). We performed chromatin immunoprecipitation (ChIP)
analysis using primary lung-resident fibroblasts isolated from TGFa
mice on Dox for 8 weeks. ChIP analysis using WT1-specific anti-
body compared with control isotype antibody revealed that WT1
bound to the AURKB gene, suggesting the role of WT1 in AURKB
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expression (Fig 2E). We next overexpressed WT1 in HEK293 cells
co-transfected with AURKB promoter fused with luciferase reporter
and observed increased luciferase activity compared to cells
transfected with control plasmids (Fig 2F). These results support
that WT1 functions as a positive regulator of AURKB by directly







Figure 1. Multiple growth factors upregulate AURKB in severe fibrotic lung disease.
A Quantification of AURKB transcripts in non-IPF lung-derived resident fibroblasts treated with indicated mitogens for 16 h. *P < 0.05, ***P < 0.0005, and
****P < 0.00005, 1-way ANOVA (n = 4).
B Quantification of AURKB gene transcripts in isolated fibroblasts from non-IPF and IPF lung stromal cell cultures. **P < 0.005, unpaired t-test (n = 6).
C IPF and non-IPF lung sections were immunostained using AURKB antibody (n = 4). Representative images were obtained at 40× magnification. Scale bar: 40 lm.
Dotted area: black; myofibroblastic core, blue; active fibrotic front. Arrows indicate AURKB positive cells.
D Immunoblots of Aurkb and Aurka in total lung lysates of normal (CCSP/) and fibrotic (CCSP/TGFa) mice fed with Dox for 6 weeks. Quantification was performed
using phosphor imager software and normalization was done using loading control Gapdh. *P < 0.05, unpaired t-test (n = 4).
E Immunostaining was performed using AURKB antibody in lung sections of control (CCSP/) and TGFa (CCSP/TGFa) mice on Dox for 6 weeks (n = 6). Representative
images were obtained at 20× (low; Scale bar: 100 lm) and 63× (high; Scale bar: 30 lm) magnification. Dashed box indicates area of the section showing in high
magnification.
F Western blot analysis of Aurkb in total lung lysates from saline and bleomycin-treated mice. Quantification was performed using phosphor imager software, and
normalization was done using loading control Gapdh. **P < 0.005, unpaired t-test (n = 4–5).
Data information: All data were presented as mean  SEM. Exact P values are shown in Appendix Table S6.
Source data are available online for this figure.
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AURKB functions as a positive regulator for fibroblast
proliferation and survival
To gain insight into the role of AURKB in fibroblast activation, we
assessed gene expression changes using next-generation sequencing
in fibroblasts isolated from the lungs of TGFa mice on Dox for
10 days treated with either control- or AURKB-specific siRNA for
72 h. Knockdown of AURKB resulted in significant loss of its tran-
scripts in resident fibroblasts (Fig EV3A). As shown in the heat
map, the knockdown of AURKB has resulted in 800 upregulated and
1248 downregulated genes (≥ 1.5-fold change; P value FDR ≤ 0.05)
(Fig EV3B). To identify potential AURKB-driven pro-fibrotic gene
transcripts in IPF, we next compared differentially expressed genes
in IPF lungs (GSE53845) (DePianto et al, 2015) and AURKB-specific
siRNA-treated lung fibroblasts. We identified multiple transcripts
that were either upregulated (141 genes) or downregulated (50
genes) by AURKB in IPF (Fig 3A and Appendix Table S1). Func-
tional enrichment analysis of these negatively correlated gene sets
(i.e., genes upregulated in IPF lungs but downregulated in AURKB-
specific siRNA-treated lung fibroblasts and vice versa) using the
ToppFun application of the ToppGene Suite (Chen et al, 2009) iden-
tified several major fibroblast-specific biological processes. These
include cell proliferation, apoptosis, and ECM production (Fig 3B).
Co-immunofluorescence staining was performed with anti-AURKB
and anti-Ki-67 antibodies on lung sections from normal and TGFa
mice on Dox for 4 weeks. We observed a notable increase in the
number of AURKB and Ki-67-positive cells in the fibrotic lesions of
TGFa mice on Dox for 4 weeks compared to control mice (Fig 3C).
Both AURKB and Ki-67 co-localized to the same cells by immunoflu-
orescence staining, and the number of dual positive cells for both
AURKB and Ki-67 was significantly greater in the lungs of TGFa
mice compared to normal mice (Fig 3D).
To test whether AURKB induces fibroproliferation, we assessed
the impact of AURKB knockdown on BrdU incorporation in fibrob-
lasts isolated from the lungs of IPF or TGFa mice on Dox for
2 weeks. We observed a significant decrease in BrdU incorporation
in fibroblasts treated with AURKB-specific siRNA compared to
control siRNA (Fig 3E). With the loss of AURKB in fibroblasts, we
observed a significant decrease in TGFa-induced fibroproliferation
(Fig 3F). To establish the mechanisms in AURKB-driven fibroprolif-
eration, we assessed changes in AURKB-driven IPF network genes
predicted to regulate fibroproliferation, such as PLK1 and CCNA2,
in fibroblasts treated with AURKB-specific siRNA compared with





Figure 2. WT1 regulates AURKB expression.
A Human IPF lung fibroblasts were transiently transfected with control or WT1 siRNA for 72 h and AURKB transcripts were quantified. ****P < 0.00005, unpaired t-test
(n = 4).
B Lung-resident fibroblasts from TGFa mice on Dox for 4 weeks were transiently transfected with control or WT1 siRNA for 72 h, and AURKB transcripts were
quantified. ****P < 0.00005, unpaired t-test (n = 4).
C Immunoblot analysis of AURKB and WT1 in the lysates of non-IPF fibroblasts transduced with control or WT1-adenoviral particles for 72 h. **P < 0.005, unpaired
t-test (n = 3).
D Quantification of AURKB transcripts in primary fibroblasts from IPF lung treated with either control or WT1 siRNA and stimulated with media or TGFa (100 ng/ml) for
16 h. ****P < 0.00005, unpaired t-test (n = 4).
E Primary lung-resident fibroblasts were isolated from stromal cultures of TGFa mice placed on Dox for 8 weeks. Cell lysates were prepared, and the ChIP assay was
performed with anti-WT1 antibody or normal rabbit IgG as a negative control using AURKB gene promoter-specific PCR primers. Non-immunoprecipitated DNA is
represented as input DNA (product size, 104 bp). ***P < 0.0005, unpaired t-test (n = 2).
F AURKB promoter luciferase activity was measured in HEK293 cells transfected with control or WT1 overexpressing (OE) vector. ****P < 0.00005, one-way-ANOVA
(n = 6).
Data information: All data were presented as mean  SEM. The above data were a representative of two independent experiments with similar results. P values were
shown in Appendix Table S6.
Source data are available online for this figure.
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sufficient to attenuate the expression of AURKB-dependent genes
involved in fibroproliferation (Fig 3G). These findings establish that
AURKB functions as a positive regulator of fibroproliferation in IPF.
In progressive fibrosis, fibroblasts transform to myofibroblasts
and develop resistance to apoptosis, thereby promoting excessive
ECM deposition and the expansion of fibrotic lung lesions (Than-
nickal & Horowitz, 2006; Kasam et al, 2019). To test whether
myofibroblasts express AURKB, we performed co-immunofluores-
cence staining of AURKB and aSMA in lung sections from control
and TGFa mice at 6 weeks on Dox, when fibrosis is well estab-
lished. Our co-immunostaining show that AURKB localized in the
nucleus and aSMA being in cytoplasm of myofibroblasts in the
subpleural fibrotic lesions of TGFa mice on Dox for 6 weeks
(Fig 3H). To test whether AURKB induces fibroblast survival, the
mature fibrotic lesions of IPF or TGFa mice on Dox for 6 weeks
were cultured to isolate fibroblasts and apoptosis was quantified in
fibroblasts treated with either control or AURKB-specific siRNA.
Notably, the loss of AURKB transcripts was sufficient to induce
apoptosis in fibroblasts from IPF or TGFa mice (Fig 3I). To under-
stand the mechanisms in AURKB-driven fibroblast survival, we
quantified the expression of genes involved in apoptosis by RT–
PCR. The genetic loss of AURKB was sufficient to induce the expres-
sion of pro-apoptotic gene transcripts such as Bak, Bax, and Fas in
fibroblasts isolated from the lungs of IPF or TGFa mice on Dox for
6 weeks (Fig 3J and K). Together, the above findings establish that
increased AURKB expression contributes to apoptosis resistance in
mesenchymal cells.
Barasertib attenuates fibroblast activation
To test whether the inhibition of AURKB activity alters fibroblasts
activation, we assessed the proliferation of fibroblasts isolated from
the lungs of IPF or TGFa mice on Dox for 4 weeks. Upon treatment
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significant reduction in BrdU incorporation in fibroblasts isolated
from IPF and TGFa model (Fig 4A and B). In support, the percent of
PCNA-positive cells was significantly reduced in barasertib-treated
IPF fibroblasts compared with vehicle (Fig 4C). Consistent with the
loss of AURKB in fibroblasts, we observed a dose-dependent attenu-
ation of TGFa-induced fibroblast proliferation when treated with
barasertib compared to vehicle (Fig 4D). Similar to the loss of
AURKB expression, inhibition with barasertib reduced the expres-
sion of AURKB-driven genes involved in fibroproliferation such as
CCNA2 and PLK1 (Fig EV4). Previous studies from our group, and
others, have demonstrated a pathogenic role for enhanced survival
of multiple mesenchymal cells in the development and maintenance
of pulmonary fibrosis (Kasam et al, 2019). To evaluate the effect of
AURKB inhibition on apoptotic clearance of fibroblasts, we isolated
fibroblasts from IPF lungs and assessed the impact of barasertib
treatment on cleaved caspase 3 activity. Treatment with barasertib
resulted in a significant increase in caspase 3/7 activity compared to
vehicle (Fig 4E). Thus, either the loss of expression or activity of
AURKB is sufficient to mitigate fibroblast activation, including
fibroproliferation and survival in IPF fibroblasts and in lung fibrob-
lasts from the TGFa mouse model.
Barasertib attenuates TGFa-induced pulmonary fibrosis in vivo
To test whether treatment with barasertib prevents the development
of lung fibrosis, TGFa mice were concomitantly treated with Dox to
induce TGFa expression and either barasertib (40 mg/kg body
weight) or vehicle twice per day for 4 weeks (Fig 5A). Induction of
TGFa caused extensive subpleural, perivascular, and peribronchial
fibrosis (Fig 5B). TGFa-activated mice that were concomitantly
given barasertib showed reduced collagen staining with infrequent
scattered small fibrotic areas. Further, we observed a significant
decrease in the lung weights and hydroxyproline levels in TGFa
mice treated with barasertib compared to vehicle-treated mice
(Fig 5C and D). In agreement with the transcriptional changes, we
observed a significant decrease in lung collagen levels in TGFa mice
treated with barasertib compared to vehicle-treated TGFa mice on
Dox for 4 weeks (Fig 5C). Further, gene expression analysis by RT–
PCR demonstrated a reduction in the expression of ECM genes such
as Col1a, Col5a, and Fn1 in barasertib-treated TGFa mice compared
to vehicle-treated TGFa mice (Fig 5E). Together, these findings
suggest that inhibition of AURKB activity by barasertib attenuates
progressive fibrotic changes in TGFa mice.
To determine whether the anti-fibrotic effects of barasertib
in vivo are due to decreased proliferation in fibrotic lung lesions, we
next immunostained the lung sections with Ki-67 and found a signif-
icant increase in immunoreactivity for Ki-67 in the subpleural and
adventitial fibrotic lesions of TGFa mice treated with vehicle
compared to non-fibrosis control mice (Fig 6A). Notably, TGFa mice
treated with barasertib displayed a significant reduction in Ki-67
staining in both subpleural and adventitial fibrotic lesions. Addition-
ally, immunoblot analysis in lung lysates demonstrated decreased
PCNA levels in the barasertib-treated TGFa mice compared to vehi-
cle-treated TGFa mice (Fig 6B). The transcript levels for genes
implicated in cell proliferation, including Aurkb, were significantly
reduced in barasertib-treated TGFa mice lungs compared to vehicle-
treated mice (Fig 6C). Also, we observed a significant reduction in
the expression of Wt1 in the lungs of TGFa mice treated with bara-
sertib compared to vehicle-treated TGFa mice (Fig EV5).
To determine whether AURKB inhibition influences the progres-
sion of established and ongoing pulmonary fibrosis following
3 weeks of Dox treatment when fibrosis is already manifest, TGFa
mice were administered barasertib while remaining on Dox for an
additional 3 weeks (Fig 7A). The right lung weights were increased
in TGFa mice compared to control mice on Dox for 6 weeks. This
increase in lung weights was attenuated in TGFa mice treated with
◀ Figure 3. AURKB functions as a positive regulator of fibroproliferation and survival.A Venn diagram depicting the comparison and overlap of differentially expressed genes in IPF lungs and AURKB siRNA-treated fibrotic fibroblasts. The dashed box
indicates genes that were up- (141 genes) or downregulated (DN, 50 genes) in IPF lungs compared with AURKB siRNA knockdown gene expression signatures.
B AURKB-driven genes activated in IPF were analyzed using ToppFun and visualized using Cytoscape. Red- and blue-colored circles represent genes that are up or
downregulated, respectively, in IPF lungs. The turquoise-colored circle represents enriched biological processes for the inversely correlated genes between AURKB
siRNA knockdown and IPF.
C Lung sections from control and TGFa mice fed with Dox food for 4 weeks were stained for AURKB (green) and Ki-67(red). Merged image shows cells that co-express
AURKB and Ki-67 (yellow).
D Quantification of Ki-67+ and AURKB+ double-positive cells was performed using five confocal images per mice in control and TGFa mice. Images were obtained at
40× magnification. Scale bar: 50 lm. ****P < 0.00005, unpaired t-test (n = 4).
E Proliferation was measured in primary lung-resident fibroblast isolated from either IPF lung or TGFa mice and treated with either control or AURKB siRNA.
****P < 0.00005, unpaired t-test (n = 9–11).
F Proliferation was measured in primary lung-resident fibroblasts isolated from stromal cultures of TGFa mice on Dox for 2 weeks and transiently transfected with
control or AURKB siRNA and stimulated with TGFa (20 ng/ml) for 24 h. ****P < 0.00005, 1-way ANOVA (n = 9–11).
G Quantification of CCNA2 and PLK1 transcripts in human IPF fibroblasts transiently transfected with control or AURKB siRNA for 72 h. **P < 0.005, ***P < 0.0005,
unpaired t-test (n = 3).
H Lung sections from control and TGFa mice fed with Dox food for 6 weeks were stained for AURKB (green) and aSMA (red). Images were obtained at
40× magnification. Scale bar: 50 lm. (n = 4).
I Quantification of apoptotic cells using Incucyte ZOOM (caspase 3/7-positive cells) in lung-resident fibroblasts isolated from IPF and TGFa mice on Dox for 6 weeks
and treated with control or AURKB siRNA for 72 h. **P < 0.005, ****P < 0.00005, 2-way ANOVA (n = 4).
J Quantification of Bak, Bax, and Fas gene transcripts in human IPF lung-resident fibroblasts treated with either control or AURKB siRNA for 72 h. **P < 0.005,
***P < 0.0005, unpaired t-test (n = 3).
K Quantification of Bak, Bax, and Fas gene transcripts in lung-resident fibroblasts isolated from TGFa mice and treated with either control or AURKB siRNA for 72 h.
*P < 0.005, **P < 0.005, unpaired t-test (n = 3).
Data information: All data were presented as mean  SEM. The above data were a representative of two independent experiments with similar results. Exact P values
are shown in Appendix Table S6.
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barasertib when compared to vehicle-treated TGFa mice (Fig 7B).
Western blot analysis revealed a significant decrease in Col1a and
Fn1 protein levels in barasertib-treated TGFa mice lungs compared
to vehicle-treated (Fig 7C). TGFa mice on Dox for 6 weeks develop
severe fibrotic lung disease including subpleural and adventitial
thickening and the loss of lung function. Intervention therapy with
barasertib resulted in a marked reduction in subpleural and adventi-
tial fibrosis as evidenced by masons trichrome staining (Fig 7D).
Notably, barasertib treatment resulted in improvements in resis-
tance and elastance and prevented a decrease in lung compliance
during TGFa-induced pulmonary fibrosis (Fig 7E). To assess possi-
ble effects of doxycycline and DMSO treatments individually on
inflammation and fibrosis, CCSP-rtTA and TetO-TGFa mice were
treated with Dox-containing food for 6 weeks or vehicle containing
5% DMSO for 3 weeks. We observed no significant effect of doxycy-
cline or DMSO treatments on inflammation, lung collagen deposi-
tion, and lung function compared to untreated littermate control
mice (Appendix Fig S1).
Barasertib attenuates bleomycin-induced pulmonary fibrosis
in vivo
To substantiate our hypothesis that AURKB inhibition with bara-
sertib attenuates pulmonary fibrosis, we used an alternative mouse
model of bleomycin-induced pulmonary fibrosis (Singh et al, 2017;
Sontake et al, 2018). Pulmonary fibrosis was induced in wild-type
mice by treating with bleomycin intradermally 5 days per week for
4 weeks, while the last 2 weeks they received either vehicle or bara-
sertib (Fig 8A). Lung sections stained with Masson’s trichrome
demonstrated significant increase in collagen staining in the lung
parenchyma of bleomycin-treated mice compared with vehicle-
treated control mice. This increase in Masson’s trichrome staining
was attenuated with barasertib treatment compared to vehicle-
treated mice during bleomycin-induced pulmonary fibrosis (Fig 8B).
Similarly, barasertib treatment resulted in a significant decrease in
the lung hydroxyproline levels compared to vehicle-treated fibrotic
mice (Fig 8C). To determine whether barasertib treatment has any
negative effect on AURKB-regulated gene network, we analyzed
total lung transcripts using RT–PCR. In particular, transcripts of
Col1a, Col3a, Col5a, Col14a, Col15a, Ccna2, Ccnb1, and Fas were
significantly decreased in barasertib-treated mice compared to vehi-
cle-treated fibrotic mice (Fig 8D). Barasertib treatment also caused a
significant decrease in the aSMA protein levels in the lung lysates of
barasertib-treated mice compared to vehicle-treated fibrotic mice
(Fig 8E). Taken together, our findings provide complementary
in vivo evidence that barasertib treatment attenuates collagen depo-
sition and plays a protective role in pulmonary fibrosis.
Discussion
We report a mitotic kinase called aurora kinase B that links fibrob-
last activation with fibrotic lung remodeling in IPF. AURKB is a
member of the aurora kinases family and a mitotic kinase that plays
a critical role in multiple steps of the cell cycle, including cytokinesis
(Willems et al, 2018). AURKB is overexpressed in a wide range of
tumor types and has been considered a marker of prognosis
(Portella et al, 2011; Tang et al, 2017; Chieffi, 2018). Our results
demonstrate that AURKB is upregulated in fibroblasts isolated from
fibrotic lung lesions of IPF and a mouse model of TGFa-induced
pulmonary fibrosis. Our immunostainings suggest upregulation of
AURKB in a subset of mesenchymal cells in subpleural
fibrotic lesions and fibrotic foci of IPF lungs. Co-immunostainings
with Ki67 and aSMA show that AURKB is upregulated in both






Figure 4. Blockade of AURKB activity impacts fibroblast proliferation
and survival.
A Proliferation was assessed using BrdU incorporation assay in human IPF
fibroblasts treated with indicated doses of barasertib for total of 48 h.
****P < 0.00005, 1-way ANOVA (n = 9–11).
B Proliferation was assessed using BrdU incorporation assay in fibroblasts
isolated from TGFa mice lung and treated with indicated doses of
barasertib for total of 48 h. ***P < 0.0005, 1-way ANOVA (n = 9–11).
C Primary lung-resident fibroblasts isolated from TGFa mice on Dox for
4 weeks were treated with vehicle or 5 lM barasertib for 48 h and
immunostained using PCNA antibody. Images were obtained at 40×
magnification. Scale bar: 50 lm. The number of PCNA-positive cells and
total DAPI-positive cells was quantified using MetaMorph image analysis
software. Proliferation is indicated as the percentage of proliferating cells in
total DAPI-positive cells. ****P < 0.00005, unpaired t-test (n = 3–4).
D Proliferation was measured in primary fibroblasts treated with TGFa
(20 ng/ml) and indicated doses of barasertib for 48 h. **P < 0.005, 1-way
ANOVA (n = 9–11).
E Quantification of apoptotic cells using Incucyte ZOOM (caspase 3/7-positive
cells) in resident fibroblasts isolated from IPF lung stromal cultures and
treated with vehicle or 5 lM Barasertib. ****P < 0.00005, 2-way ANOVA
(n = 4).
Data information: All data were presented as mean  SEM. The above data
were a representative of two independent experiments with similar results.
P values were shown in Appendix Table S6.
Source data are available online for this figure.
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Using knockdown studies, we identified AURKB-driven gene
networks that were fibroblast-specific and dysregulated in IPF, such
as genes involved fibroproliferation, survival, and ECM production.
In support of its pro-fibrotic actions, loss of AURKB resulted in
attenuation of fibroproliferation and increased apoptotic clearance
of fibroblasts, suggesting that AURKB is a positive regulator of
fibroblast activation. Furthermore, AURKB is known to induce
proliferation and survival in cancer cells during tumor development.
Elevated expression of AURKB in thyroid anaplastic carcinoma cells
can induce higher growth rate, and inhibition of AURKB expression
by RNA interference has resulted in reduced proliferation of these
cells (Sorrentino et al, 2005). Similarly, the knockdown of Epstein–
Barr nuclear antigen 3C (EBNA3C)-induced AURKB expression
resulted in increased activity of caspases 3 and 9 along with poly
(ADP-ribose) polymerase 1 (PARP1) cleavage (Jha et al, 2013). Inhi-
bition of AURKB activity by barasertib attenuated fibroproliferation
and induces the apoptotic clearance in fibroblasts of IPF and TGFa
mice. We confirmed that pharmacological inhibition of AURKB
activity or siRNA-mediated inhibition of AURKB expression is suffi-
cient to inhibit the expression of genes such as Plk1 and CcnA2
implicated in fibroblast proliferation. With AURKB inhibition, we
observed a significant increase in the expression of pro-apoptotic
genes such as Bak, Bax, and Fas, which are downstream effectors in
caspase-mediated apoptotic clearance. This agrees with our recent
report that apoptosis-resistant fibroblasts isolated from fibrotic lung





Figure 5. In vivo Barasertib treatment prevents from TGFa induced lung fibrosis.
A Schematic illustration of barasertib preventive treatment protocol. Control and TGFa mice were treated with either vehicle or barasertib (40 mg/kg; twice a day) for
4 weeks, while they were fed with Dox-containing food.
B Representative images of Masson’s trichrome-stained lung sections from the vehicle- and barasertib-treated mice. Images were obtained at 10× magnification. Scale
bar: 200 lm.
C Quantification of right lung weight of mice treated with vehicle or barasertib. ***P < 0.0005, ****P < 0.00005, 1-way ANOVA (n = 8–10 mice/group).
D Quantification of total lung hydroxyproline levels in mice treated with vehicle or barasertib. *P < 0.05, ***P < 0.0005, 1-way ANOVA (n = 8–10 mice/group).
E Quantification of Col1a, Col5a, and Fn1 gene transcripts in total lung of mice treated with vehicle or barasertib. ***P < 0.0005, ****P < 0.00005, 1-way ANOVA (n = 8
mice/group).
Data information: All data were presented as mean  SEM. P values were shown in Appendix Table S6.
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compared to normal fibroblasts (Kasam et al, 2019). Similarly, a
recent publication from Bogen et al showed that barasertib induces
apoptosis in multiple types of MYCN-amplified neuroblastoma cell
lines (Bogen et al, 2015). This phenomenon was also documented
in multiple cancer types, including breast cancer, colorectal cancer,
melanoma, and leukemia (Gully et al, 2010; Alferez et al, 2012;
Yamauchi et al, 2013; Porcelli et al, 2015).
Our previous work demonstrates a role for WT1 in fibroblast
activation, including fibroproliferation, myofibroblast transforma-
tion, and ECM gene expression in the pathogenesis of IPF (Sontake
et al, 2015, 2018). This work expands upon these findings, demon-
strating that WT1 upregulates AURKB expression in fibroblasts. The
fibroproliferative changes detected in TGFa mice may be the result
of WT1-driven AURKB expression. ChIP analysis and the use of an
AURKB promoter-driven luciferase assay revealed that WT1 directly
interacts with the promoter elements of AURKB to drive its expres-
sion in fibroblasts. Our previous study demonstrates that WT1 regu-
lates the myofibroblast transformation by interacting with aSMA
promoter region and promoting its expression (Sontake et al, 2018).
Hence, we speculate that WT1 promotes the fibroblasts activation at
least in part by regulating the expression of AURKB. These findings
posit a new role for WT1-AURKB axis in fibroproliferation.
However, future studies are needed to evaluate possible binding
partners and other molecular regulators downstream of WT1 and
AURKB in fibroblast activation and pulmonary fibrosis.
These findings have therapeutic implications as they suggest
targeting AURKB activity inhibits fibroblast activation, particularly
when multiple pro-fibrotic growth factors promoting alternative
fibroproliferative pathways are present. We evaluated the in vivo
effects of AURKB inhibition by barasertib using mouse models of
TGFa- and bleomycin-induced pulmonary fibrosis. Published studies
have shown elevated levels of TGFa in the lung lavage fluid and
fibrotic lung lesions of IPF patients compared to healthy controls
(Madtes et al, 1988; Baughman et al, 1999). In support, overexpres-
sion of TGFa in mice has resulted in the development of pathologic
fibrotic lesions similar to those found in IPF, including fibroprolifer-
ation, resistance to apoptosis, and subpleural fibrosis migrating into
the interstitium, myofibroblast transformation, and a progressive
decline in lung function (Hardie et al, 2004, 2010; Sontake et al,
2018; Kasam et al, 2019). Moreover, gene expression profiles after
expression of TGFa were more similar to IPF samples compared to
bleomycin model (Hardie et al, 2007; Kasam et al, 2019). In a recent
study, we demonstrated that the FDA-approved anti-fibrotic agent
nintedanib inhibited TGFa-induced pulmonary fibrosis by limiting
both fibroproliferation and myofibroblast survival (Kasam et al,
2019). Similarly, in the TGFa model used in the current study,
in vivo treatment with barasertib either as a preventive or as a thera-
peutic strategy led to decreased fibroproliferation and myofibroblast
accumulation in the pathogenesis of pulmonary fibrosis. Our lung
physiology measurements using FlexiVent have demonstrated that
treatment of mice with barasertib improved lung function during
TGFa-induced pulmonary fibrosis. These physiological changes are
in agreement with observed changes in the expression of genes
associated with proliferation, apoptosis, and ECM. Furthermore, we
demonstrated anti-fibrotic effects of barasertib using a chronic




Figure 6. In vivo barasertib treatment attenuates mesenchymal proliferation.
A Lung sections from vehicle- and barasertib-treated mice were immunostained using Ki-67 antibody. Representative images were obtained at 20× magnification. Scale
bar: 50 lm.
B Immunoblot analysis in lung lysates from vehicle- and barasertib-treated mice using PCNA antibody. Gapdh is used as loading control. **P < 0.005, 1-way ANOVA
(n = 4–5 mice/group).
C Quantification of Aurkb, Plk1, and CcnA2 gene transcripts in total lungs of mice treated with vehicle or barasertib. **P < 0.005, ***P < 0.0005, ****P < 0.00005, 1-way
ANOVA (n = 8 mice/group).
Data information: All data were presented as mean  SEM. P values were shown in Appendix Table S6.
Source data are available online for this figure.
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et al, 2016a; Singh et al, 2017; Sontake et al, 2018). A large body of
evidence supports the concept that macrophages, fibrocytes, and
other immune cells secrete paracrine factors to cause excessive
fibroproliferation (Madala et al, 2014; Desai et al, 2018). Impor-
tantly, the frequency of proliferating fibroblasts was elevated in the
expanding areas of fibrotic foci and infusion of these proliferating
mesenchymal progenitors resulted in the progressive fibrosis in
mice (Xia et al, 2017). However, the expansion of fibrotic lesions is
also attributed to the resistance to programmed cell death in
myofibroblasts that accumulate in the mature fibrotic lesions
(Horowitz & Thannickal, 2019; Hinz & Lagares, 2020). In support,
myofibroblasts isolated from IPF lungs displayed abnormalities in
apoptotic pathways, senescence, and defective autophagy (Patel
et al, 2012; Alvarez et al, 2017; Kasam et al, 2019). Also, it is now
increasingly recognized that the pathogenesis of IPF is complex
likely in part due to the molecular and functional heterogeneity of
fibroblasts and other lung cells (Rock et al, 2011; Reyfman et al,
2018; Tsukui et al, 2020). Therefore, use of inhibitors that block
both proliferation and myofibroblast survival could be more benefi-
cial to attenuate established and ongoing pulmonary fibrosis. Bara-
sertib is currently in clinical studies, and it has been evaluated in
patients with solid malignant tumors and myeloid leukemia (Lowen-
berg et al, 2011). Moreover, barasertib treatment in murine xeno-
graft model has potentiated the anti-proliferative properties of
vincristine and daunorubicin (Yang et al, 2007). In human xenograft





Figure 7. Therapeutic barasertib treatment reduces established and ongoing lung fibrosis.
A Schematic illustration of barasertib treatment protocol. Control and TGFa mice were treated with either vehicle or barasertib (40 mg/kg; twice a day) for last
3 weeks, while they were fed with Dox-containing food for total of 6 weeks.
B Quantification of right lung weight of mice treated with vehicle and barasertib. **P < 0.005, ****P < 0.00005, 1-way ANOVA (n = 9–10 mice/group).
C Western blot analysis in lung lysates from vehicle- and barasertib-treated mice using Col1a and Fn1 antibodies. Gapdh is used as loading control. *P < 0.05,
**P < 0.005, ***P < 0.0005, 1-way ANOVA (n = 4–5 mice/group).
D Representative images of Masson’s trichrome-stained lung section from mice treated with vehicle and barasertib. Images were obtained at 10× magnification. Scale
bar: 200 lm.
E Quantification of lung mechanics in mice treated with vehicle and barasertib. *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.00005, 1-way ANOVA (n = 9–10
mice/group).
Data information: All data were presented as mean  SEM. P values were shown in Appendix Table S6.
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tumor types. Barasertib was shown to inhibit the growth of human
colon, lung, and hematologic tumor xenografts by reducing cell divi-
sion and inducing apoptosis-mediated cell death (Wilkinson et al,
2007). Barasertib was tested in clinical trials for patients with acute
myeloid leukemia (AML) and various other tumors (Tsuboi et al,
2011; Dennis et al, 2012; Collins et al, 2015). The anti-tumor effects
of barasertib were enhanced when used in combination with
dexamethasone (Evans et al, 2008). Overall, these results indicate
that fibroblast-specific expression of AURKB is a critical driver of
fibroblast activation and that therapeutic targeting of AURKB may
serve as an ideal therapy in IPF.
In summary, we have identified and described the pathological
role for AURKB in fibroblast activation and pulmonary fibrosis. We
identified a role for WT1 in AURKB expression and AURKB-driven
transcripts involved in proliferation and survival of fibroblasts
in the pathogenesis of pulmonary fibrosis. Our preclinical
findings support the use of barasertib as an anti-fibrotic agent to
attenuate fibroblast activation involved in established and ongoing
pulmonary fibrosis.
Materials and Methods
Mouse models of TGFa and bleomycin-induced
pulmonary fibrosis
Clara cell-specific promoter (CCSP)-driven rtTA mice (CCSP-rtTA)
and TGFa overexpressing mice were generated as described previ-
ously (Hardie et al, 2004). Hemizygous (TetO)7-cmv TGFa mice
were crossed to CCSP-rtTA mice to generate bitransgenic mice
(CCSP-rtTA;TGFatg) and littermate controls (CCSP-rtTA/). Both
male and female gender mice at age 10–16 weeks were used for all
the experiments. Spatiotemporal overexpression of TGFa was
induced by feeding the mice with doxycycline (62.5 mg/kg) contain-
ing chow. Stock solutions of barasertib (AZD-1152-HQPA; Selleck-
chem, TX, USA) were prepared freshly in vehicle (5% DMSO and
50% PEG-300). Previous pharmacokinetic studies have indicated
that sustained and efficient AURKB inhibition could be achieved
with barasertib administered at a dose range of 25–50 mg/kg every




Figure 8. Therapeutic barasertib treatment attenuates bleomycin-induced lung fibrosis.
A Schematic illustration of barasertib treatment protocol. Mice were treated with either vehicle or barasertib (40 mg/kg; twice a day) for last 2 weeks, while they were
injected intradermally with either saline or bleomycin 5 days per week for total of 4 weeks.
B Representative images of Masson’s trichrome-stained lung section from mice treated with vehicle and barasertib. Images were obtained at 10× magnification. Scale
bar: 200 lm.
C Quantification of total lung hydroxyproline in mice treated with vehicle and barasertib. *P < 0.05, ***P < 0.0005, 1-way ANOVA (n = 7–8 mice/group).
D Quantification of Col1a1, Col3a, Col5a, Col14, Col15, aSma, Ccna2, and Fas gene transcripts in total lungs of mice treated with vehicle or barasertib. *P < 0.05,
**P < 0.005 ***P < 0.0005, ****P < 0.00005, 1-way ANOVA (n = 6 mice/group).
E Quantification of aSma protein levels in lung lysates from vehicle- and barasertib-treated mice. Gapdh is used as loading control. Data are presented as
mean  SEM. **P < 0.005, unpaired t-test (n = 5 mice/group).
Data information: All data were presented as mean  SEM. P values were shown in Appendix Table S6.
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we treated mice with vehicle or barasertib (40 mg/kg body weight)
by intraperitoneal injections twice a day with 12-h intervals. For
in vivo intervention studies, all groups of mice were started on Dox
for total 6 weeks. At the beginning of week 3, mice were treated
with either vehicle or barasertib for the final 3 weeks of the study
(Sontake et al, 2017). For bleomycin-induced mouse model, 10- to
14-week-old C57BL/6J mice (JAX Stock # 000664) were treated
intradermally with saline or bleomycin (6 U/kg body weight) 5 days
per week for 4 weeks intradermally as described (Singh et al, 2017).
For in vivo intervention studies, all mice were treated with saline or
bleomycin for the total 4 weeks, and at the beginning of week 2,
mice were treated with either vehicle or barasertib for the final
2 weeks of the study. All the mice were housed under specific
pathogen-free conditions, and all animal experiments were
performed under protocols approved by the Institutional Animal
Care and Use Committee of the Cincinnati Children’s Hospital
Research Foundation.
Human samples
De-identified human IPF and control non-IPF lung tissues were
obtained from the Interstitial Lung Disease Biorepository at the
University of Michigan Medical School and provided by Steven
Huang in the Department of Internal Medicine. Specimens consisted
of paraffin-embedded and freshly isolated lung tissue of patients
who underwent lung transplantation for IPF. IPF was diagnosed
according to the American Thoracic Society consensus criteria
(Raghu et al, 2011). Lung samples from donors with no lung disease
were used as normal lung biopsies. All tissues were acquired using
research protocols and informed consent and approved by the
Michigan Medicine Institutional Review Board (HUM00105694).
The experiments conformed to the principles set out in the WMA
Declaration of Helsinki (https://www.wma.net/policies-post/wma-
declaration-of-helsinki-ethical-principles-for-medical-research-invol
ving-human-subjects/) and the Department of Health and Human
Services Belmont Report (http://www.hhs.gov/ohrp/humansubjec
ts/guidance/belmont.html).
RNA isolation and RT–PCR
Total RNA from primary cells and lung tissue was prepared using
RNeasy kit (Qiagen Sciences, Valencia, CA) as described previously
(Kasam et al, 2019). Real-time PCR was performed using the
CFX384 Touch Real-Time PCR detection system and SYBR select
master mix (Bio-Rad, Hercules, CA). Target gene transcripts in each
sample were normalized to mouse hypoxanthine guanine phospho-
ribosyltransferase (Hprt) or human beta-actin or Gapdh. All the
real-time primer details are provided in Appendix Tables S2 and S3.
Western blot
Western blot analysis was performed as described earlier (Madala
et al, 2016a). Briefly, cell lysate was prepared either from primary
cells or from lung tissue using the RIPA lysis buffer containing
protease and phosphatase inhibitors. The protein concentrations in
the supernatants were quantified using BCA kit (Thermo Fisher
Scientific, Waltham, MA). After SDS–PAGE separation, proteins
were transferred to nitrocellulose membrane and then were probed
using specific primary antibodies followed by detection with HRP-
conjugated secondary antibodies. Bands were quantified using the
volume integration function of the phosphor imager software, Multi-
gage (Fujifilm, Valhalla, NY). Details of antibodies used in the
Western blot are provided in Appendix Table S5.
Histology and immunohistochemistry
Histology and immunostaining were performed as described previ-
ously (Sontake et al, 2017). Briefly, lungs were inflated and fixed
with formalin. Paraffin-embedded lungs were cut into 5-lM sections
and stained for masons trichrome. For immunostaining, lung
sections were deparaffinized, antigen retrieval was performed using
10 mM citric acid (pH 6.0), and sections were incubated in blocking
solution before they were incubated with specific primary antibody
overnight. DAB-stained sections were mounted and visualized using
a bright field microscope (Leica Microsystems).
Immunofluorescence and confocal imaging
Immunofluorescence, confocal imaging, and cell quantification were
performed as described previously (Madala et al, 2014). Briefly,
OCT medium-embedded lung sections were immunostained using
specific primary antibodies and followed by detection with appropri-
ate secondary antibodies conjugated with Alexa Fluor-488 or 568 or
647. For immunocytochemistry, primary cells were fixed with
methanol or 4% paraformaldehyde and were blocked using BSA
solution before they were incubated with primary antibodies. Lung
sections or primary cells were stained with DAPI for nuclear stain-
ing. Confocal images were collected using a Nikon AIR-A1 laser
scanning confocal microscope. Imaris (version 7.2.0; Bit plane) was
used for image analysis and automated cell quantification. Details of
the antibodies used for immunostaining are provided in
Appendix Table S4.
Quantification of apoptotic death
Apoptotic cell death was measured as described previously using
IncuCyte ZOOM real-time imaging system (Kasam et al, 2019).
Briefly, primary cells were incubated in Caspase 3/7 Green apopto-
sis assay reagent (Caspase 3/7 substrate conjugated to green fluo-
rophore; Essence Bioscience) at a final concentration of 5 lM/ml.
Time-lapse fluorescence imaging was performed using the IncuCyte
ZOOM system (Essen BioScience); 9 images per well at 20× magnifi-
cation were collected every 2 h for 24–48 h. The average number of
green objects produced by the apoptotic cells was measured using
Incucyte ZOOM software 2015A.
BrdU cell proliferation assay
Cell proliferation was quantified using BrdU kit (Cell signaling
technology, Denver, CO) as described previously (Sontake et al,
2017). Briefly, primary lung-resident fibroblasts that were either
transiently transfected with Aurkb siRNA or treated with vehicle
or barasertib were incubated with BrdU labeling solution for 24 h.
The cells were then fixed 24 h after BrdU labeling, and
immunodetection of BrdU was performed according to the manu-
facturer’s protocol.
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siRNA-mediated knockdown
Stealth siRNA-mediated transfection was performed in human or
mouse lung-resident fibroblasts using Lipofectamine 3000 transfec-
tion kit as described previously (Sontake et al, 2015). Stealth nega-
tive control, Aurkb stealth siRNA, and WT1 stealth siRNA were
purchased from Invitrogen: Human Aurora kinase B (Cat#
HSS190048), mouse Aurora kinase B (Cat# MSS209696), human
WT1 (Cat# HSS111390), mouse WT1 (Cat# MSS212628), and stealth
negative control siRNA (Cat# 12935300).
Adenoviral transduction
Human lung-resident fibroblasts purified from lung stromal cultures
using CD45-microbeads by negative selection were transduced with
control or WT1-overexpressing adenoviral particles (000488A, Abm,
Richmond, Canada) as described previously (Sontake et al, 2018).
Cells were harvested 48–72 h post-viral transduction.
Human and mouse lung primary mesenchymal cell culture
Human and mouse lung mesenchymal cell cultures were prepared
as described previously (Sontake et al, 2018). Human and mouse
mesenchymal cells were cultured in DMEM with 10% FBS and
IMDM with 5% FBS media, respectively. Primary cells used in the
experiments were between passages 1 and 5.
Hydroxyproline measurement and lung mechanics
Hydroxyproline was assessed by a colorimetric assay, as previously
described (Madala et al, 2016b). Lung function parameters such as
resistance, elastance, and compliance were measured using a
computerized Flexi Vent system (SCIREQ, Montreal, Canada) as
described previously (Singh et al, 2017).
RNA-sequencing and computational analysis
RNA was prepared from lung-resident fibroblasts from TGFa mice
on Dox for 10 days and transfected with control or Aurkb siRNA.
RNA-sequencing and differential gene expression analysis were
performed as described previously (Sontake et al, 2018). Aurkb
siRNA-generated gene signature was queried against already avail-
able IPF gene signature (GSE53845) (DePianto et al, 2015). Func-
tional enrichment analysis of the negatively correlated gene sets
between IPF lungs and Aurkb siRNA-treated fibroblasts was
analyzed using the ToppFun application of the ToppGene Suite
(Chen et al, 2009).
ChIP-seq PCR assay
ChIP-seq PCR was performed using the ChIP assay kit (Cell signal-
ing technology, Denver, CO) as described previously (Sontake et al,
2018). Briefly, lung-resident fibroblasts were purified from lung stro-
mal culture of CCSP/TGFa mice on Dox-containing food for
8 weeks. Cells were cross-linked with 1% formaldehyde, and
immunoprecipitation was performed with anti-WT1 (catalog 12609-
1-AP, Proteintech, Rosemont, IL) or isotype control IgG (Cell Signal-
ing Technology, Denver, CO) at 4°C as described in the
manufacturer’s protocol. DNA was purified, and ChIP-qPCR was
performed using the CFX384 Touch Real-Time PCR detection system
and SYBR select master mix (Bio-Rad, Hercules, and CA).
Luciferase assay
HEK293 cells were transiently co-transfected with vectors containing
empty promoter or AURKB promoter fused with luciferase reporter
(SwitchGear Genomics, Menlo Park, CA) and pLJM1 alone or with
pLJM1 vector expressing WT1 using lipofectamine-3000 transfection
reagent (Invitrogen). After 72 h, cells were lysed, and Renilla luci-
ferase activity was measured using LightSwitch Luciferase Assay
Reagent (SwitchGear Genomics) in a Flex Station 3 microplate
reader (Molecular Devices). Luciferase activity is reported as rela-
tive luminescence units (RLU).
Statistical analysis
For in vivo studies, we used the sample size of seven to ten per
group based on our published studies using preclinical mouse
model of pulmonary fibrosis. We considered sex as a biological
variable and randomized both male and females animals in groups
to analyze animal data in aggregate. Also, the details of experi-
mental groups were blinded to investigators for biochemical and
histological evaluations. All data were analyzed for statistical
significance using Prism (version 8; Graph Pad). We used t-test to
compar between two groups and one-way ANOVA with Turkey’s
multiple comparison post-test to compare between more than two
experimental groups. All data were expressed as the mean  SEM.
The paper explained
Problem
Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease
caused by activation of multiple pro-fibrotic pathways in fibroblasts
to induce excessive proliferation, survival, and ECM secretion. Hence,
understanding converging points in fibroblast activation is essential to
develop novel and effective therapies against IPF.
Results
Aurora kinase B is a key mitotic kinase that we found upregulated in
lung fibroblasts of IPF and mouse models of TGFa- and bleomycin-
induced pulmonary fibrosis. This increase in AURKB expression in
lung-resident fibroblasts is driven by multiple pro-fibrotic growth
factors and a transcription factor called Wilms tumor 1. Using both
in vitro and in vivo models of pulmonary fibrosis, we demonstrate
that AURKB upregulation is involved in fibroblast activation and the
pharmacologic inhibition of AURKB attenuates ongoing pulmonary
fibrosis in mouse models of TGFa- and bleomycin-induced pulmonary
fibrosis.
Impact
This study provides the first evidence that the AURKB functions as a
positive regulator for fibroproliferation and survival in the progressive
expansion of fibrotic lesions in IPF. Our new findings support the
mechanism of the WT1-AURKB axis to induce fibroproliferation in IPF.
Barasertib treatment is an effective therapy to attenuate ongoing
fibrosis in mouse models of severe fibrotic lung disease and may
prove useful as a potential therapeutic option for IPF.
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Data were considered statistically significant for P < 0.05. The
exact P values for each figure can be found in Appendix Table S6.
Data availability
The RNA-seq datasets produced in this study are available at Gene
Expression Omnibus (GEO) under the accession number GSE1538
98 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15
3898).
Expanded View for this article is available online.
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